Literature DB >> 6216999

Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.

M R Daha, D J Kok, L A Van Es.   

Abstract

Activation of complement may result in the generation of the amplification convertase C3bBb. This convertase can be stabilized by properdin (P) or C3NeF. C3bBbP is susceptible to inactivation by beta 1H, while C3bBbNeF is relatively resistant. Since it has been shown that the human erythrocyte C3b receptor (CR1) is able to inactivate C3bBbP, the inactivating action of CR1 on C3bBbNeF was investigated CR1 is at least five times more efficient than beta 1H in inactivating C3bBbNeF. Kinetic studies revealed that CR1 induces an enhanced biphasic kinetics of decay of C3bBbNeF; further purification of this C3NeF preparation by cation exchange chromatography showed that this phenomenon is dependent on the population of C3NeF. Finally CR1 is also able to inactivate fluid phase C3bBbNeF.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6216999      PMCID: PMC1536848     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Some physical-chemical properties of chicken gamma-globulins and their pepsin and papain digestion products.

Authors:  H S Tenenhouse; H F Deutsch
Journal:  Immunochemistry       Date:  1966-01

2.  Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).

Authors:  L G Hunsicker; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

3.  The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

Authors:  P A Nicol; P J Lachmann
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

4.  C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

5.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

6.  Initiation of C3 cleavage in the alternative complement pathway.

Authors:  D T Fearon; K F Austen
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

7.  Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement.

Authors:  D T Fearon; K F Austen; S Ruddy
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

8.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

9.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

View more
  15 in total

1.  Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.

Authors:  T E Mollnes; Y C Ng; D K Peters; T Lea; J Tschopp; M Harboe
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

2.  C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.

Authors:  Y C Ng; D K Peters
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

Review 3.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

4.  Immunohistochemical studies of the spleen in hairy-cell leukemia.

Authors:  C J Meijer; F Albeda; P Van der Valk; P J Spaander; J Jansen
Journal:  Am J Pathol       Date:  1984-05       Impact factor: 4.307

5.  Characterization of B-cell non-Hodgkin's lymphomas. A study using a panel of monoclonal and heterologous antibodies.

Authors:  P van der Valk; J Jansen; M R Daha; C J Meijer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1983

6.  Complement depletion accelerates the clearance of immune complexes from the circulation of primates.

Authors:  F J Waxman; L A Hebert; J B Cornacoff; M E VanAman; W L Smead; E H Kraut; D J Birmingham; J M Taguiam
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

7.  C3 nephritic factor and hypocomplementaemia in a clinically healthy individual.

Authors:  A T Gewurz; S M Imherr; S Strauss; H Gewurz; C Mold
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

Review 8.  Idiopathic membranoproliferative glomerulonephritis in childhood.

Authors:  C D West
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

9.  Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.

Authors:  S Ito; N Tamura; T Fujita
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

10.  Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.

Authors:  Danielle Paixão-Cavalcante; Margarita López-Trascasa; Lillemor Skattum; Patricia C Giclas; Timothy H Goodship; Santiago Rodríguez de Córdoba; Lennart Truedsson; B Paul Morgan; Claire L Harris
Journal:  Kidney Int       Date:  2012-08-01       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.